NCT07240896 is a EARLY_PHASE1 clinical trial of Group 1: DSL101 Low dose in Wilsons Disease, sponsored by DSciLab Co., Ltd..

Who is sponsoring NCT07240896?

NCT07240896 is sponsored by DSciLab Co., Ltd..

What drugs are being tested in NCT07240896?

Interventions in NCT07240896: Group 1: DSL101 Low dose, Group 2: DSL101 Medium dose, Group 3: DSL101 High dose.

What condition does NCT07240896 study?

NCT07240896 studies Wilsons Disease.

Is NCT07240896 still recruiting?

NCT07240896 is currently recruiting now. Last updated 15 January 2026.

Last reviewed 2026-01-15 · How we verify

NCT07240896

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Clinical Study on the Treatment of Wilson Disease With ATP7B mRNA/LNP (DSL101)

Recruiting now EARLY_PHASE1 Last updated 15 January 2026

What this trial tests

EARLY_PHASE1 trial testing Group 1: DSL101 Low dose in Wilsons Disease in 18 participants. Currently enrolling.

Timeline

31 December 2025

Primary endpoint
1 April 2028

1 April 2029

Quick facts

Lead sponsor	DSciLab Co., Ltd.
Phase	EARLY_PHASE1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	31 December 2025
Primary completion	1 April 2028
Estimated completion	1 April 2029
Sites	1 location across China

Drugs / interventions tested

Group 1: DSL101 Low dose — full drug profile →
Group 2: DSL101 Medium dose — full drug profile →
Group 3: DSL101 High dose — full drug profile →

Conditions studied

Wilsons Disease — all drugs for Wilsons Disease →

Sponsor

DSciLab Co., Ltd. — full company profile →

Who can join

18 and older, any sex, with Wilsons Disease. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Incidence of adverse events and serious adverse events
Time frame: up to 56 weeks

Sponsor's own description

This study adopted an open, single-arm, non-randomized, dose-escalation research design, aiming to evaluate the safety, tolerability, preliminary efficacy, pharmacokinetic and immunogenicity characteristics of single and multiple intravenous infusions of DSL101 in patients with Wilson's disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07240896 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by DSciLab Co., Ltd.
Last refreshed: 15 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07240896.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing